Invex Therapeutics Ltd

ASX:IXC

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2019-07-05. The firm is focused on the development and commercialisation of Presendin (Exenatide) for neurological conditions relating to raised intracranial pressure. The firm received written responses from the United States Food and Drug Administration (FDA) Division of Neurology relating to its proposed Phase III clinical trial design for Presendin in Idiopathic Intracranial Hypertension (IIH). Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. The firm focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The firm intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimized to treat different neurological conditions.